ALVERINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H27N
Molecular Weight	281.4351
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CCN(CCCC1=CC=CC=C1)CCCC2=CC=CC=C2

InChI

InChIKey=ZPFXAOWNKLFJDN-UHFFFAOYSA-N

InChI=1S/C20H27N/c1-2-21(17-9-15-19-11-5-3-6-12-19)18-10-16-20-13-7-4-8-14-20/h3-8,11-14H,2,9-10,15-18H2,1H3

HIDE SMILES / InChI

Molecular Formula	C20H27N
Molecular Weight	281.4351
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Alverine is a smooth muscle relaxant used for the treatment irritable bowel syndrome. Alverine may increase calcium influx during action potentials due to inhibition of the inactivation of L-type calcium channels, but may also suppress evoked activity by inhibiting the sensitivity of contractile proteins to calcium.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-gated L-type calcium channel 92	Activator 1,430
Hepatocyte nuclear factor 4-alpha 8	Activator 1,430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Irritable bowel syndrome 60	Primary		Approved 8,429	Alverine
Anxiety 267	Primary		Preclinical	Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
2574 pg/mL	120 mg single, oral		ALVERINE plasma	Homo sapiens
2841.78 pg/mL	250 mg single, oral		PARA HYDROXY ALVERINE plasma	Homo sapiens

AUC

Value	Dose	Co-administered	Analyte	Population
15562.3 pg × h/mL	120 mg single, oral		ALVERINE plasma	Homo sapiens
19755.5 pg × h/mL	250 mg single, oral		PARA HYDROXY ALVERINE plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
11.37 h	120 mg single, oral		ALVERINE plasma	Homo sapiens
9.84 h	250 mg single, oral		PARA HYDROXY ALVERINE plasma	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
60 mg 3 times / day multiple, oral Recommended	unhealthy, 34 years n = 1	Disc. AE: Hepatitis acute...
60 mg 3 times / day multiple, oral Recommended	unhealthy, mean age 46.5 years n = 207	Disc. AE: Eye swelling... Other AEs: Nausea, Abdominal pain upper...

Showing 1 to 2 of 2 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Hepatitis acute	Disc. AE	60 mg 3 times / day multiple, oral Recommended	unhealthy, 34 years n = 1
Asthenia	0.5%	60 mg 3 times / day multiple, oral Recommended	unhealthy, mean age 46.5 years n = 207
Eye swelling	0.5% Disc. AE	60 mg 3 times / day multiple, oral Recommended	unhealthy, mean age 46.5 years n = 207
Abdominal pain upper	1.4%	60 mg 3 times / day multiple, oral Recommended	unhealthy, mean age 46.5 years n = 207
Vertigo	1.9%	60 mg 3 times / day multiple, oral Recommended	unhealthy, mean age 46.5 years n = 207

Showing 1 to 5 of 7 entries

Previous1 2Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:518413	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:518413
ChemicalBook	CB5333673	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5333673
ZINC	ZINC000001481966	http://zinc15.docking.org/substances/ZINC000001481966
eMolecules	618386	https://www.emolecules.com/cgi-bin/more?vid=618386

Showing 1 to 4 of 4 entries

Previous1Next

PubMed

Show entries

Title	Date	PubMed
Acute hepatitis caused by alverine associated with anti-lamin A and C autoantibodies.	1997 Aug	9288616
Effects of alverine citrate on cat intestinal mechanoreceptor responses to chemical and mechanical stimuli.	1999 Apr	10215743
Rectal antinociceptive properties of alverine citrate are linked to antagonism at the 5-HT1A receptor subtype.	2001 Oct	11697552
Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study.	2010 Mar	20003095